Cargando…
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991290/ http://dx.doi.org/10.1186/2051-1426-1-S1-P259 |
| _version_ | 1782312409944293376 |
|---|---|
| author | Ansell, Stephen Northfelt, Donald Flinn, Ian Burris, Howard Dinner, Shira Villalobos, Victor Sikic, Branimir Pilja, Lana Yellin, Michael Keler, Tibor Davis, Thomas |
| author_facet | Ansell, Stephen Northfelt, Donald Flinn, Ian Burris, Howard Dinner, Shira Villalobos, Victor Sikic, Branimir Pilja, Lana Yellin, Michael Keler, Tibor Davis, Thomas |
| author_sort | Ansell, Stephen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991290 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39912902014-05-05 A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors Ansell, Stephen Northfelt, Donald Flinn, Ian Burris, Howard Dinner, Shira Villalobos, Victor Sikic, Branimir Pilja, Lana Yellin, Michael Keler, Tibor Davis, Thomas J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991290/ http://dx.doi.org/10.1186/2051-1426-1-S1-P259 Text en Copyright © 2013 Ansell et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Ansell, Stephen Northfelt, Donald Flinn, Ian Burris, Howard Dinner, Shira Villalobos, Victor Sikic, Branimir Pilja, Lana Yellin, Michael Keler, Tibor Davis, Thomas A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_full | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_fullStr | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_full_unstemmed | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_short | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_sort | phase i study of an agonist anti-cd27 human antibody (cdx-1127) in patients with advanced hematologic malignancies or solid tumors |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991290/ http://dx.doi.org/10.1186/2051-1426-1-S1-P259 |
| work_keys_str_mv | AT ansellstephen aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT northfeltdonald aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT flinnian aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT burrishoward aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT dinnershira aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT villalobosvictor aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT sikicbranimir aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT piljalana aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT yellinmichael aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT kelertibor aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT davisthomas aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT ansellstephen phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT northfeltdonald phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT flinnian phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT burrishoward phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT dinnershira phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT villalobosvictor phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT sikicbranimir phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT piljalana phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT yellinmichael phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT kelertibor phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT davisthomas phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors |